The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Triple–Hormone-Receptor Agonist Retatrutide for Obesity
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These drugs act by simultaneously targeting three different agonists GLP-1R, the GIPR, and the GCGR.149–151”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [150]
In the citing paper
“These receptors each have independent yet complementary roles in the treatment of diabetes and obesity.150,152,153”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [150]
Citations
Cites
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Caleyachetty, R., Thomas, G. N., Toulis, K. A., Mohammed, N., Gokhale, K. M., Balachandran, K., & Nirantharakumar, K. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.763 · Cited by 574
Alkhouri, N., Herring, R., Kabler, H., Kayali, Z., Hassanein, T., Kohli, A., Huss, R. S., Zhu, Y., Billin, A. N., Damgaard, L. H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.003 · Cited by 230
Metabolically healthy obesity and cardiovascular events: A nationwide cohort study
Fauchier, G., Bisson, A., Bodin, A., Herbert, J., Semaan, C., Angoulvant, D., Ducluzeau, P., Lip, G. Y. H., & Fauchier, L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14492 · Cited by 80
Self-citationThe future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44
Harrison, S. A., Bédossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R. S., Taub, R. A., Labriola, D., Moussa, S., Neff, G. W., Sanyal, A. J., et al. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)00440-3 · Cited by 23
Triple G Agonists — A Home Run for Obesity?
Patti, M. (2023) · New England Journal of Medicine · doi:10.1056/nejme2307282 · Cited by 7
Research works printed but not linked: 1
- Yuen M Brancale J Earle RL et al. A systematic review and evaluation of current evidence reveals 195 obesity-associated disorders. Presented at ObesityWeek 2016 Annual Meeting New Orleans November 2–4 2016:T-P-3166. abstract.
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“150,152,153 Activation of the GLP-1R can enhance insulin secretion, reduce glucagon secretion, delay gastric emptying, 154 and suppress appetite.”
BackgroundTherapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F., & Mehal, W. Z. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 169
“An example is the peptide retatrutide, which has shown potent effects on weight loss, and trials in MASH are underway 127 .”
Dubin, R. L., Heymsfield, S. B., Ravussin, E., & Greenway, F. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15913 · Cited by 47
“119,120 10 | CONCLUSIONS Despite major efforts to optimize methods for safely and effectively losing weight, we still have not discovered an effective treatment that avoids at least some loss of FFM.”
Fan, W., Bradford, T. M., & Török, N. J. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15184 · Cited by 25
Role of the Intestine and Its Gut Microbiota in Metabolic Syndrome and Obesity
Busch, C. B. E., Bergman, J. J. G. H. M., Nieuwdorp, M., & van Baar, A. C. G. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002730 · Cited by 27
“ThetriplehormoneRA,retatrutide (50) with 24% weight loss, may be added to the list in the near future.”
Background
Metadata
- Authors
- Bisson, A., Fauchier, G., & Fauchier, L.
- Affiliations
- Yale University (US)
- Harvard University (US)
- Eli Lilly (United States) (US)
- ORCID
- Laurent Fauchier
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-10-26
- Volume
- 389
- Issue
- 17
- Pages
- 1628-1630
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387933553
- Cited by
- 21
- References
- 9
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 12 · 2023: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- retatrutide, obesity, GLP-1 receptor agonists, GIP receptor agonist, weight loss, obesity pharmacotherapy
- MeSH terms
- Hormones, Humans, Obesity, Gonadal Steroid Hormones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Triple–Hormone-Receptor Agonist Retatrutide for Obesity. https://app.cochat.ai/papers/10.1056/nejmc2310645
- The paper
- Bisson, A., Fauchier, G., & Fauchier, L. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. https://doi.org/10.1056/nejmc2310645
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.